Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002512668 | SCV003023658 | pathogenic | Bardet-Biedl syndrome 3; Retinitis pigmentosa 55 | 2023-10-06 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 169 of the ARL6 protein (p.Gly169Ala). This variant is present in population databases (rs104893679, gnomAD 0.0009%). This missense change has been observed in individual(s) with Bardet-Biedl syndrome (PMID: 15314642). It has also been observed to segregate with disease in related individuals. This variant is also known as 859G>C G169A. ClinVar contains an entry for this variant (Variation ID: 2041). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects ARL6 function (PMID: 19236846). For these reasons, this variant has been classified as Pathogenic. |
OMIM | RCV000002121 | SCV000022279 | pathogenic | Bardet-Biedl syndrome 3 | 2004-09-01 | no assertion criteria provided | literature only | |
OMIM | RCV000002122 | SCV000022280 | risk factor | Bardet-Biedl syndrome 1, modifier of | 2004-09-01 | no assertion criteria provided | literature only |